Hendin B N, Streem S B, Levin H S, Klein E A, Novick A C
Department of Urology, Cleveland Clinic Foundation, Ohio 44195, USA.
J Urol. 1999 Mar;161(3):783-5.
We determine whether diagnostic retrograde ureteroscopy for evaluation of upper tract transitional cell carcinoma adversely affects survival outcomes in terms of urothelial and metastatic tumor recurrence, and tumor-free and overall survival.
A total of 96 patients underwent total nephroureterectomy or resection of the distal ureter with a bladder cuff for upper tract transitional cell carcinoma. Of the patients 48 (study group) had undergone preoperative diagnostic ureteroscopy while 48 (control group) had not. Grade and stage of disease were compared, and time to recurrence, and disease-free and overall survival were analyzed.
Grade and stage of disease were equivalent in both groups. There were no significant differences in recurrence rates, time to recurrence or mortality between the groups. Metastases developed in 9 patients (18.8%) in the control group and 6 (12.5%) in the study group (p = 0.58), while 5 (10.4%) in each group died of metastases of upper tract carcinoma (p = 1.00). Kaplan-Meier estimates were 0.67 and 0.71 for metastasis-free survival at 5 years (p = 0.25, not significant) and 0.87 and 0.76 for overall 5-year survival (p = 0.75, not significant) for the study and control groups, respectively.
Diagnostic ureteroscopy has no clinically apparent adverse effect on long-term or disease specific survival of patients with upper tract transitional cell carcinoma who subsequently undergo standard definitive surgical management.
我们确定用于评估上尿路移行细胞癌的诊断性逆行输尿管镜检查是否会在上皮性和转移性肿瘤复发以及无瘤生存和总生存方面对生存结果产生不利影响。
共有96例患者因上尿路移行细胞癌接受了全肾输尿管切除术或输尿管远端及膀胱袖口切除术。其中48例患者(研究组)术前行诊断性输尿管镜检查,48例患者(对照组)未行该检查。比较两组疾病的分级和分期,并分析复发时间、无病生存和总生存情况。
两组疾病的分级和分期相当。两组在复发率、复发时间或死亡率方面无显著差异。对照组有9例患者(18.8%)发生转移,研究组有6例患者(12.5%)发生转移(p = 0.58),每组各有5例患者(10.4%)死于上尿路癌转移(p = 1.00)。研究组和对照组5年无转移生存率的Kaplan-Meier估计值分别为0.67和0.71(p = 0.25,无显著性差异),5年总生存率分别为0.87和0.76(p = 0.75,无显著性差异)。
对于随后接受标准确定性手术治疗的上尿路移行细胞癌患者,诊断性输尿管镜检查对其长期生存或疾病特异性生存无明显临床不良影响。